{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:32:27Z","timestamp":1777984347370,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project of China","award":["2025ZD0544300"],"award-info":[{"award-number":["2025ZD0544300"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08035-y","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:05:06Z","timestamp":1773900306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety analysis of CAR-T cell salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment"],"prefix":"10.1186","volume":"24","author":[{"given":"Fuli","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanzheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xindi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-6575","authenticated-orcid":false,"given":"Jia","family":"Cong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"3","key":"8035_CR1","first-page":"83","volume":"102","author":"E Sabattini","year":"2010","unstructured":"Sabattini E, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83\u20137.","journal-title":"Pathologica"},{"key":"8035_CR2","doi-asserted-by":"publisher","first-page":"102443","DOI":"10.1016\/j.ctrv.2022.102443","volume":"110","author":"S Poletto","year":"2022","unstructured":"Poletto S, et al. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev. 2022;110:102443.","journal-title":"Cancer Treat Rev"},{"key":"8035_CR3","doi-asserted-by":"crossref","unstructured":"Lamure S et al. Clinical and product features associated with outcome of DLBCL patients to CD19-targeted CAR T-cell therapy. Cancers. 2021 Aug 25;13(17):4279.","DOI":"10.3390\/cancers13174279"},{"key":"8035_CR4","doi-asserted-by":"crossref","unstructured":"Abramson JS et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet (London, England). 2020;396(10254): 839\u2013852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"issue":"26","key":"8035_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"S Neelapu, Sattva","year":"2017","unstructured":"Neelapu, Sattva S, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New Engl J Med vol. 2017;377(26):2531\u201344.","journal-title":"New Engl J Med vol"},{"key":"8035_CR6","unstructured":"Brooks TR et al. Jul. Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. 2025;29117."},{"issue":"7","key":"8035_CR7","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1007\/s00277-025-06438-3","volume":"104","author":"R Gurion","year":"2025","unstructured":"Gurion R, et al. Efficacy and safety of Glofitamab in patients with R\/R DLBCL in real life setting- a retrospective study. Annals Hematol vol. 2025;104(7):3821\u20137.","journal-title":"Annals Hematol vol"},{"key":"8035_CR8","doi-asserted-by":"crossref","unstructured":"Farhat M et al. Sep. From R-CHOP to revolution: How CAR T-Cells, ADCs, and bispecific antibodies are transforming DLBCL treatment. Crit Rev Oncol\/Hematol. 2025;215:104917.","DOI":"10.1016\/j.critrevonc.2025.104917"},{"issue":"4","key":"8035_CR9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.4143\/crt.2025.440","volume":"57","author":"J Kim","year":"2025","unstructured":"Kim J, Kim SJ. Advances in T-Cell-directed immunotherapy for adult mature B-Cell Lymphoma: a comprehensive review of CAR T-Cell and bispecific antibody therapies. Cancer Res Treat. 2025;57(4):905\u201322.","journal-title":"Cancer Res Treat vol"},{"issue":"7","key":"8035_CR10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood.2023022682","volume":"144","author":"BJ Brinkmann","year":"2024","unstructured":"Brinkmann BJ, et al. CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models. Blood. 2024;144(7):784\u20139.","journal-title":"Blood vol"},{"key":"8035_CR11","doi-asserted-by":"crossref","unstructured":"Schipani M et al. Oct. Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy. Cancers. 8 2025;17(19):3258.","DOI":"10.3390\/cancers17193258"},{"key":"8035_CR12","doi-asserted-by":"crossref","unstructured":"Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol: Official J Am Soc Clin Oncol 2014;32(27): 3059\u201368.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"8035_CR13","doi-asserted-by":"crossref","unstructured":"Barrington SF et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol: Official J Am Soc Clin Oncol. 2014;32(27): 3048-58.","DOI":"10.1200\/JCO.2013.53.5229"},{"issue":"4","key":"8035_CR14","doi-asserted-by":"publisher","first-page":"e70103","DOI":"10.1002\/hon.70103","volume":"43","author":"Organizing Committee of the Lugano Classification Workshop","year":"2025","unstructured":"Organizing Committee of the Lugano Classification Workshop. Current Status of Revisions to the Lugano Classification in Lymphoma. Hematol Oncol vol. 2025;43(4):e70103.","journal-title":"Hematol Oncol vol"},{"key":"8035_CR15","doi-asserted-by":"crossref","unstructured":"Lee DW et al. ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl. 2019;25(4):625\u201338.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"issue":"1","key":"8035_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, et al. Using the common terminology criteria for adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. CTCAE versi\u00f3n 5.0. Evaluaci\u00f3n de la gravedad de los eventos adversos dermatol\u00f3gicos de las terapias antineopl\u00e1sicas. Actas Dermo-sifiliograficas. 2021;112(1):90\u20132.","journal-title":"Actas dermo-sifiliograficas"},{"issue":"1","key":"8035_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell Lymphoma. New Engl J Med. 2019;380(1):45\u201356.","journal-title":"New Engl J Med vol"},{"issue":"13","key":"8035_CR18","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1080\/10428194.2021.1953016","volume":"62","author":"A Minson","year":"2021","unstructured":"Minson A, Dickinson M. Glofitamab CD20-TCB bispecific antibody. Leuk Lymphoma. 2021;62(13):3098\u2013108.","journal-title":"Leuk lymphoma vol"},{"issue":"3","key":"8035_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood.2024024526","volume":"144","author":"G Crochet","year":"2024","unstructured":"Crochet G, et al. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood. 2024;144(3):334\u20133381.","journal-title":"Blood vol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08035-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08035-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08035-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:20:01Z","timestamp":1777335601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08035-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8035"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08035-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8473352\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of Beijing Tongren Hospital approved the study (TREC2022-KY103) and we conducted the study in accordance with the Declaration of Helsinki. Informed consent from patients was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent obtained directly from patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"Not commissioned; externally peer reviewed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Provenance and peer review"}},{"value":"None declared.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"598"}}